SCHEMBL4771665

SCHEMBL4771665

CCOC(=O)c1c(C)nc2c(cnn2CC)c1-c1ccnc(Cl)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.51
LMNA P02545 3/20 0.51
ALDH1A1 P00352 3/20 0.51
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
MAPT P10636 2/20 0.51
NPSR1 Q6W5P4 2/20 0.51
GMNN O75496 1/20 0.51
USP2 O75604 1/20 0.51
TP53 P04637 1/20 0.51
CYP1A2 P05177 1/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2D6 P10635 1/20 0.51
CYP2C9 P11712 1/20 0.51
TSHR P16473 1/20 0.51
MAPK1 P28482 1/20 0.51
CYP2C19 P33261 1/20 0.51
THPO P40225 1/20 0.51
BLM P54132 1/20 0.51
PMP22 Q01453 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4770189 0.89 PDE4B (0.43) SMN1; SMN2LMNAALDH1A1MEN1KMT2A
SCHEMBL4778036 0.88 MAPT (0.46) SMN1; SMN2LMNAALDH1A1MEN1KMT2A
SCHEMBL4776322 0.85 PDE4B (0.44) SMN1; SMN2LMNAALDH1A1MEN1KMT2A
SCHEMBL4769974 0.85 SMN1; SMN2 (0.52) SMN1; SMN2LMNAALDH1A1MEN1KMT2A
SCHEMBL5123696 0.84 LMNA (0.55) SMN1; SMN2LMNAALDH1A1MEN1KMT2A
SCHEMBL4774892 0.83 MAPT (0.36) SMN1; SMN2LMNAALDH1A1MEN1KMT2A
SCHEMBL4778624 0.81 MAPT (0.36) SMN1; SMN2LMNAALDH1A1MEN1KMT2A
SCHEMBL4772382 0.80 NR3C1 (0.36) SMN1; SMN2LMNAALDH1A1MEN1KMT2A
SCHEMBL4772379 0.80 NR3C1 (0.36) SMN1; SMN2LMNAALDH1A1MEN1KMT2A
SCHEMBL4778988 0.79 MAT2A (0.42) SMN1; SMN2LMNAALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7459451-B2 e.g. 1-Ethyl-4-(5-methyl-3-pyridyl)-6-phenyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid; phosphodiesterase (PDE)-IV inhibitor or tumor necrosis factor (TNF)- alpha antagonist; autoimmune diseases, antidepressant, anxiolytic agent; polychondritis, scleroderma, fibrosis, arthritis, Alzheimer's disease ASTELLAS PHARMA INC. (JP) 2008-12-02 US disclosed
EP-1763528-B1 PYRAZOLOPYRIDINE DERIVATIVES ASTELLAS PHARMA INC (JP) 2008-11-26 EP disclosed
US-20060004003-A1 Pyrazolopyridine derivatives ASTELLAS PHARMA INC. (JP) 2006-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004003-A1 Pyrazolopyridine derivatives PDE4A, PDE3B, PDE5A SMN1; SMN2 2957/4885LMNA 3462/4885ALDH1A1 774/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.